1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2016

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 50 pages

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2016’, provides an overview of the Functional (Non Ulcer) Dyspepsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Functional (Non Ulcer) Dyspepsia
- The report reviews pipeline therapeutics for Functional (Non Ulcer) Dyspepsia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Functional (Non Ulcer) Dyspepsia therapeutics and enlists all their major and minor projects
- The report assesses Functional (Non Ulcer) Dyspepsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Functional (Non Ulcer) Dyspepsia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Functional (Non Ulcer) Dyspepsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Functional (Non Ulcer) Dyspepsia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Functional (Non Ulcer) Dyspepsia Overview 6
Therapeutics Development 7
Pipeline Products for Functional (Non Ulcer) Dyspepsia - Overview 7
Pipeline Products for Functional (Non Ulcer) Dyspepsia - Comparative Analysis 8
Functional (Non Ulcer) Dyspepsia - Therapeutics under Development by Companies 9
Functional (Non Ulcer) Dyspepsia - Therapeutics under Investigation by Universities/Institutes 10
Functional (Non Ulcer) Dyspepsia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Functional (Non Ulcer) Dyspepsia - Products under Development by Companies 14
Functional (Non Ulcer) Dyspepsia - Products under Investigation by Universities/Institutes 15
Functional (Non Ulcer) Dyspepsia - Companies Involved in Therapeutics Development 16
Almirall, S.A. 16
Eisai Co., Ltd. 17
Ironwood Pharmaceuticals, Inc. 18
RaQualia Pharma Inc. 19
Yuhan Corporation 20
Zensun (Shanghai) Sci and Tech Co., Ltd. 21
Zeria Pharmaceutical Co., Ltd. 22
Functional (Non Ulcer) Dyspepsia - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Drug Profiles 30
acotiamide hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
cinitapride - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
IW-9179 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
rabeprazole sodium DR - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
RQ-00000010 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
RQ-00201894 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
YH-12852 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
ZS-07 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Functional (Non Ulcer) Dyspepsia - Recent Pipeline Updates 41
Functional (Non Ulcer) Dyspepsia - Dormant Projects 45
Functional (Non Ulcer) Dyspepsia - Discontinued Products 46
Functional (Non Ulcer) Dyspepsia - Product Development Milestones 47
Featured News and Press Releases 47
Oct 20, 2014: Ironwood Presents IW-9179 Phase IIa Data at American College of Gastroenterology 2014 Annual Scientific Meeting 47
Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia 47
Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables
Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H1 2016 7
Number of Products under Development for Functional (Non Ulcer) Dyspepsia - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Functional (Non Ulcer) Dyspepsia - Pipeline by Almirall, S.A., H1 2016 16
Functional (Non Ulcer) Dyspepsia - Pipeline by Eisai Co., Ltd., H1 2016 17
Functional (Non Ulcer) Dyspepsia - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 18
Functional (Non Ulcer) Dyspepsia - Pipeline by RaQualia Pharma Inc., H1 2016 19
Functional (Non Ulcer) Dyspepsia - Pipeline by Yuhan Corporation, H1 2016 20
Functional (Non Ulcer) Dyspepsia - Pipeline by Zensun (Shanghai) Sci and Tech Co., Ltd., H1 2016 21
Functional (Non Ulcer) Dyspepsia - Pipeline by Zeria Pharmaceutical Co., Ltd., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 29
Functional (Non Ulcer) Dyspepsia Therapeutics - Recent Pipeline Updates, H1 2016 41
Functional (Non Ulcer) Dyspepsia - Dormant Projects, H1 2016 45
Functional (Non Ulcer) Dyspepsia - Discontinued Products, H1 2016 46

List of Figures
Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H1 2016 7
Number of Products under Development for Functional (Non Ulcer) Dyspepsia - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Targets, H1 2016 24
Number of Products by Stage and Targets, H1 2016 24
Number of Products by Mechanism of Actions, H1 2016 26
Number of Products by Stage and Mechanism of Actions, H1 2016 26
Number of Products by Stage and Routes of Administration, H1 2016 28
Number of Products by Stage and Molecule Types, H1 2016 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H2 2016

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline ...

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H2 2016

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Caspase 7 (Apoptotic Protease Mch ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.